Menu

Amylyx Pharmaceuticals, Inc. AMLX

Full chart Compare
Set alert

Price alert · AMLX

All alert types
29.50 USD +1.88 (+6.81%)

At closeNov 6, 2026, 5:31 PM EST

29.50 0.00 0.00%

After hours · Nov 6, 5:31 PM ET

27.50 Day range 29.58
11.38 52-week range 39.66
YTD
+144.21%
1 year
+136.76%

Revenue & Expenses

Other Income → Expenses: $12.60MIncome Tax Benefit → Expenses: $393.00KExpenses → Selling, General & Admin: $114.33MExpenses → Research & Development: $104.08MExpenses → Other Operating Expenses: $141.53MGross Profit → Expenses: $45.22MRevenue → Gross Profit: $45.22MRevenue → Cost of Revenue: $42.16MNet Loss → Expenses: $301.74MOther Income$12.60MIncome Tax Benefit$393.00KGross Profit$45.22MNet Loss$301.74MCost of Revenue$42.16MExpenses$359.95MSelling, General & Admin$114.33MResearch & Development$104.08MOther Operating Expenses$141.53MRevenue$87.37M

Latest period ending Dec 31, 2025 · select a line to chart its full history

AMLX annual income statement
Fiscal yearFY 2025 Dec 31, 2025FY 2024 Dec 31, 2024FY 2023 Dec 31, 2023FY 2022 Dec 31, 2022FY 2021 Dec 31, 2021
-153.29M-314.73M38.80M-201.34M-82.69M
-144.74M-301.74M49.27M-198.38M-87.93M
-1.53-4.430.70-3.39-13.35
AMLX annual balance sheet
Fiscal yearFY 2025 Dec 31, 2025FY 2024 Dec 31, 2024FY 2023 Dec 31, 2023FY 2022 Dec 31, 2022FY 2021 Dec 31, 2021
227.64M78.84M170.92M63.24M50.38M
332.64M193.63M517.45M391.45M105.61M
27.39M28.87M84.02M50.85M17.43M
5.96M1.98M4.24M6.28M0
305.26M164.76M433.43M340.61M-151.17M
AMLX annual cash flow
Fiscal yearFY 2025 Dec 31, 2025FY 2024 Dec 31, 2024FY 2023 Dec 31, 2023FY 2022 Dec 31, 2022FY 2021 Dec 31, 2021
-123.34M-167.65M11.92M-179.87M-74.80M
14.04M75.65M92.05M-238.99M-46.41M
257.03M348.00K3.54M431.79M158.51M
-138.00K-157.00K-1.24M-2.53M-353.00K
148.80M-92.08M107.67M12.87M37.31M